| | Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patientsAbstract A case-control study was conducted to investigate possible predictors of response to antipsychotic treatment in acute schizophrenic patients. During a 14-month period, 13 female first-episode schizophrenic patients were included. According to their antipsychotic treatment response 8 weeks after admission, they were placed in either a good-response group (n = 8) or poor-response group (n = 5). Scores of the two groups differed on several items of the Positive and Negative Syndrome Scale (PANSS) at baseline and during the following 8 weeks. At baseline, the maximum scores for Conceptual disorganization, Poor rapport, Passive/apathetic social withdrawal, and Stereotyped thinking in the good-response group were lower than the corresponding minimum scores in the poor-response group. Furthermore, minimum improvements after 1 week in scores for excitement in the good-response group were higher than the maximum improvements in the corresponding scores of the poor-response group. These PANSS items might serve as simple and rapid predictors of treatment resistance. In addition, Lack of judgment and insight significantly improved by 1 week, and further improved by 5 weeks in the good-response group. This suggests that treatment in the good-response group will be optimal if provided during a hospital stay of appropriate length.
1. Introduction  The average length of a hospital stay is getting shorter. The philosophical shift toward treatment in the least restrictive setting has been accelerated by hard economic reality [1]. In Japan, especially, psychiatric wards in general hospitals have had to shorten length of hospital stay for economic reasons. Because, to date, most of these wards have not been able to treat patients successfully under this condition, the number of psychiatric wards in general hospitals is decreasing. However, medical management in general hospitals is still suitable for psychiatric emergencies and acute-phase treatment because these patients often not only have obvious physical complications but also abnormal physiological conditions such as dehydration, hypokalemia, and elevated serum concentrations of muscle enzymes [2], [3], [4]. In addition, sedation and antipsychotic treatment sometimes cause side reactions such as upper airway obstruction [5], [6] and QT prolongation [7]. Thus, general hospitals play an important role in acute-phase treatment of such patients. Treatment of the acute phase of schizophrenia should be decided not on an economic but on a clinical basis. It is not necessarily in the patients’ interest to shorten the length of their hospital stays excessively, because the sedating effect as well as the true antipsychotic effect of drug treatment requires a few weeks to manifest [8]. Lieberman et al. estimated that 83% of patients were in remission by 1 year, and that mean and median times to remission were 35.7 weeks and 11 weeks, respectively [9]. Levinson et al. reported that significant improvement was seen up to Day 22 for three of four Brief Psychiatric Rating Scale (BPRS) factors [10]. Thus, the clinical course in the early phase of schizophrenia is changing and requires clarification. Advance knowledge of the antipsychotic treatment response may help predict the clinical course in the earlyphase of schizophrenia. Lieberman et al. [11] reported that the duration of psychosis was the single most important predictive factor for 66 patients. Lieberman et al. [12] also reported that higher levels of specific negative symptoms such as affective flattening and alogia at 20 weeks were associated with longer time to remission. Kinon et al. [13] reported that at baseline nonresponders tended to have greater total Scale for the Assessment of Negative Symptoms (SANS) scores, specifically greater anhedonia-asociality scores, and that at Week 4, nonresponders continued to demonstrate greater total SANS scores as well as greater global item scores for anhedonia-asociality, affective flattening, alogia, avolition-apathy, and poor attention. Levinson et al. [10] reported that the more improved subjects did not differ significantly from the less improved subjects in the thinking disturbance factor until Day 15. Thus, though the value of symptom scores for predicting treatment response varies over the treatment period (from baseline to 20 weeks), the predictive symptoms remain similar throughout. The present study monitors: 1) the predictive symptoms for treatment response at baseline in acute schizophrenic patients; 2) the predictive symptoms for treatment response at other time points; and 3) the time course of improvement in lack of judgment and insight and other symptoms. To evaluate these, we conducted a case-control study of response to antipsychotic treatment and of predictive value of symptom scores over the course of treatment in drug-naïve acute schizophrenic patients. The purpose of this study was to determine the minimum period of acute-phase treatment that needs to be provided in psychiatric wards of general hospitals.
2. Methods  2.1. Clinical setting Most psychotic patients in the catchment area of eastern Tokyo (approximately 1,200,000 inhabitants) who require involuntary admission are taken to the 30-bed psychiatric ward of the Tokyo Metropolitan Bokuto General Hospital, in accordance with the 1995 Law Concerning Mental Health and Welfare for the Mentally Disabled. Therefore, patients are not selected. All patients admitted to the ward were examined qd by a psychiatrist licensed by the Ministry of Health and Welfare of Japanese Government to examine involuntarily admitted patients. This physician filled out an involuntary admissions form, which was submitted to the Governor of Tokyo. In cases of severe complications, the patient was admitted not to the psychiatric ward but to the Critical Care Center of our general hospital. Patients with severe complications were excluded from our study. The average hospital stay was approximately 50–60 days. 2.2. Clinical protocol Of the patients admitted during a 14-month period (July 1, 1999 to August 31, 2000), all female first-episode patients meeting the ICD-10 criteria for schizophrenia, schizotypal and delusional disorders [14] were recruited. In addition, subjects had to have a symptom severity of at least moderate on at least one of the Positive and Negative Syndrome Scale (PANSS) [15] positive symptom items. Patients who were older than 60, comorbid with alcohol or psychoactive substance abuse, or had obvious complications were excluded. All subjects received risperidone (1 to 12 mg) as an antipsychotic and also levomepromazine (0 to 200 mg) as sedative medication, if necessary, after informed consent. Flexible doses of both drugs were used as clinically required. This treatment was consistent with standard clinical practice in Japan. At baseline and at weekly intervals, the first author rated patients using the PANSS during the 8 weeks of this study. Baseline assessments were completed within 3 days of admission because, at admission, excessive excitement masked a lot of other symptoms. Patients’ functional impairment level was also rated using the Global Assessment of Functioning Scale (GAF) at baseline and 8 weeks. 2.3. Analyses Patients were considered responders if (at the end of 8 weeks) they had no rating greater than 3 on any of the PANSS positive syndrome items and the insight item (Lack of judgment and insight). Other patients were considered poor responders. Demography, clinical characteristics, and timing of response to treatment were compared between the two groups. A t test (Welch correction, if appropriate) was used for comparisons between sequential variables. If the difference between the two standard deviations was significant, Mann–Whitney U test was used. To test for the effects of responsivity on PANSS item scores, a two- (responders and poor responders) by-nine (0–8 week time points) repeated-measures ANOVA was used. The PANSS item score at each time point was compared using a post hoc Scheffe’s test. All statistical tests were two-tailed. p-Values of less than 0.05 were regarded as statistically significant.
3. Results  The number of patients admitted to the ward during the 14-month period was 188. Of these, 86 patients received F2 diagnoses using the ICD-10 system. Fifty-eight of 86 schizophrenic patients were female, and 13 were drug-naïve first-episode female patients. Thus, a total of 13 patients with a mean age of 34.2 years (SD = 12.2; range 16–53) were included. After 8 weeks, each patient was categorized as either a responder or poor responder. As shown in Table 1, age, duration of illness, body mass index, dose of risperidone and GAF score at baseline were not significantly different between the two groups. Dose of levomepromazine and length of hospital stay in the poor responder group was higher and longer than those in the responder group, respectively. One poor responder was transferred to another psychiatric hospital because of treatment resistance, so the true mean hospital stay in the poor-responder group was longer than that given in Table 1. The mean GAF score at 8 weeks in the poor-responder group was much lower than that in the responder group. | | |  | Group | N | Age | Duration of illness (M) | BMI (kg/m2) | Dose of risperidone (mg/kg) | Dose of levomepromazine * (mg/kg) | Length of hospital-stay * (days) | GAF at baseline | |  |
 | Responder | 8 | 36.4 (8.3) | 10.3 (11.2) | 20.7 (2.1) | 6.21 (2.23) | 28.1 (25.2) | 53.3 (24.2) | 14.4 (5.0) | 80.0 (7.6) |  |
 | Poor-responder | 5 | 30.4 (17.6) | 9.8 (12.2) | 21.1 (0.6) | 7.60 (2.97) | 130.0 (50.4) | 110.0 (18.8) | 16.4 (5.4) | 44.6 (9.2) |  | | | |
At baseline, there were statistically significant differences in mean scores of 13 PANSS items (1 of 7 positive, 6 of 7 negative, and 6 of 16 general psychopathology items) between the two groups. The list of the items is given in Table 2. For all but the Depression item, the mean scores of responders were lower than those of poor responders. For only the Depression item, the result was the opposite. The maximum scores of responders were less than the minimum scores of poor responders for the Conceptual disorganization, Poor rapport, Passive/apathetic social withdrawal, Stereotyped thinking, and total Negative items. The correlation coefficient calculated for item pairs revealed significant correlations as follows: Conceptual disorganization versus Poor rapport, r = .65, P = .015; Conceptual disorganization versus Passive/apathetic social withdrawal, r = .66, P = .014; Conceptual disorganization versus Stereotyped thinking, r = .69, P = .0094; Poor rapport versus Passive/apathetic social withdrawal, r = .86, P = .0002; Poor rapport versus Stereotyped thinking, r = .72, P = .0057; and Passive/apathetic social withdrawal versus Stereotyped thinking, r = .63, P = .022. Remarkably, not only were the negative syndrome items significantly correlated, but also Conceptual disorganization as a positive syndrome item was significantly correlated to the negative syndrome items. The rest of PANSS items, which did not differ significantly in mean scores between the two groups at baseline, were evaluated over time. To test for the effects of responsivity on PANSS item scores, a two- (responders and poor-responders) by-nine (0–8 week time points) repeated-measures ANOVA was used. As a result, 7 items (4 of 6 positive and 3 of 10 general psychopathology items) and the score total of the positive and general psychopathology scale showed statistically significant differences between the two groups. The list of the items is given in Table 3. The item score at each time point was compared using a post hoc Scheffe’s test. Between the point of the first significant change and baseline, the minimum changes in scores of responders were more than the maximum changes in scores of poor responders, for both the Excitement and total general psychopathology items. Remarkably, the Lack of judgment and insight score in the responder group first changed significantly at 1 week, and then changed again at 5 weeks (Fig. 1 B). This time course of Lack of judgment and insight score (showing improvement) was similar to that of other items listed in Table 3 and Fig. 1 A.
4. Discussion  Between responders and poor responders, there were no differences in demographic variables. Also, there was no difference in psychological, social, and occupational functioning (no significant difference in mean GAF score). After 8 weeks of standard treatment, significant difference in GAF scores developed, suggesting the existence of responders and poor responders. The mean dose of levomepromazine of the poor responders was higher than that of responders, indicating that poor responders needed the sedating effect of levomepromazine more because of their poor antipsychotic response to resperidone. In support, we found that the time course of Excitement scores was significantly different between the two groups despite having similar scores at baseline. 4.1. The predictive symptoms of treatment response at baseline in acute schizophrenic patients At baseline, mean scores for the items Conceptual disorganization, Negative Scale total, Blunted affect, Emotional withdrawal, Poor rapport, Passive/apathetic social withdrawal, Difficulty in abstract thinking, Stereotyped thinking, Mannerisms and posturing, Disorientation, Poor attention, Preoccupation, Active social avoidance, and Depression between the two groups were significantly different. Of these, the results of Negative Scale total, Emotional withdrawal, and Active social avoidance scores are similar to scores in a previous report in which at baseline nonresponders tended to have greater total SANS scores, and specifically greater anhedonia-asociality scores [13]. In contrast, Conceptual disorganization, Difficulty in abstract thinking, and Stereotyped thinking scores are not consistent with the findings of a previous report showing that the more responsive subjects did not differ significantly from the less responsive subjects in the thinking disturbance factor until Day 15 [10]. The Blunted affect, Passive/apathetic social withdrawal, and Poor attention results are not consistent with the finding of a previous report that at Week 4, nonresponders demonstrated greater affective flattening, alogia, avolition-apathy, or poor attention scores [13]. The Poor rapport and Mannerisms and posturing scores are similar to those in a previous report on the association between poor outcome and symptoms such as bizarre behavior, inappropriate affect, catatonia, and poor rapport [16]. Conceptual disorganization, Blunted affect, Stereotyped thinking, Negative Scale total, Poor attention, Preoccupation, Active social avoidance, and Depression scores were significantly more sensitive predictors of the treatment response than other scores. Conceptual disorganization, Blunted affect, Negative Scale total, and Preoccupation scores were the most sensitive (i.e., these mean scores were very significantly different between the two groups). Not only the differences in mean scores, but also the maximum scores of responders, which do not overlap the minimum scores of poor responders, can be used to predict the treatment response of each patient. The maximum scores of responders were less than the minimum scores of poor responders for the items Conceptual disorganization, Poor rapport, Passive/apathetic social withdrawal, Stereotyped thinking, and Negative Scale total. Therefore, these items might be specific predictors of antipsychotic treatment response. As these items are significantly correlated, observing all of them may not be necessary. Smith et al. looked at the relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder [17] and found that social behavior deficits were associated with thought disorder and neurocognitive impairments. In our study, the correlations between Conceptual disorganization as a positive syndrome item and the negative syndrome items support the findings of this previous report. Thus, Conceptual disorganization and Negative Scale total may be the most sensitive and specific predictors of antipsychotic response at baseline. 4.2. The predictive symptoms of treatment response based on the differences in the time course of clinical improvement between responders and poor responders The time course of clinical improvement in Delusion, Hallucinatory behavior, Excitement, Suspiciousness, Positive Scale total, Uncooperativeness, Unusual thought content, Lack of judgment and insight, and General psychopathology Scale total was significantly different between the two groups, despite the lack of significant differences at baseline. Significant change in Delusion, Suspiciousness, and Unusual thought content scores compared with those at baseline first occurred at 2, 2, and 1 week, respectively. The first two are almost consistent, but the last is not consistent, with a previous report indicating the more responsive subjects did not differ significantly from the less responsive subjects in the thinking disturbance factor until Day 15 [10]. The first significant changes (relative to baseline) occurred at 1 week and were in Excitement, Positive Scale total, Uncooperativeness, Unusual thought content, Lack of judgment and insight, and General psychopathology Scale total scores; these in conjunction with baseline predictors might be used to predict treatment response at 1 week. Furthermore, Delusion, Hallucinatory behavior, and Suspiciousness scores (which first significantly changed relative to baseline at 2 weeks) may be used to predict at 2 weeks and could be used in conjunction with baseline and 1-week predictors of treatment response. As to specificity, Excitement and Scale total of General psychopathology may be superior to other items because the minimum changes in scores of responders exceeded the maximum changes in scores of poor responders. Thus, prediction of treatment response and time course of clinical improvement in acute schizophrenic patients within 2 weeks might be possible. If a patient shows a low Conceptual disorganization score at baseline and sufficient decrease in Excitement score within 1 week, he or she will ordinarily recover in 5 weeks or so. By contrast, a patient with a high Conceptual disorganization score at baseline and insufficient decrease in Excitement score within 1 week cannot be expected to recover within several weeks with simple medication such as risperidone or haloperidol. Therefore, changing from simple to complex psychopharmcologic agents or adding medication, i.e., shifting medication to those used in treatment-resistant patients, within 2 weeks may be a rational strategy. Rapid prescribing as long as it is done rationally is important in clinical practice. 4.3. Time course of improvement in lack of judgment and insight and the appropriate duration of hospital stay after involuntary admission of acute schizophrenic patients In deciding involuntary admission, lack of judgment and insight is the most important factor next to self-harm or assault on others. The finding that Lack of judgment and insight score first changed significantly in the responder group at 1 week, suggests that involuntarily admitted, acute schizophrenic patients require at least 1 week of hospital stay. The explanation might be that it takes 1 week for the sedating effect of treatment to appear (refer to the first significant change in Excitement in Table 3). Furthermore, the finding that significant change in the Lack of judgment and insight score in the responder group occurred again at 5 weeks, suggests, from the point of view of clinical psychopharmacologic management, that approximately 5 weeks of hospital stay should be guaranteed (if needed) to all who are admitted involuntarily. In support of this recommendation, clinical improvement in Delusion and Hallucinatory behavior also follow a similar time course (Table 3). Five weeks of treatment appear to be necessary to establish an observable antipsychotic effect. Patients discharged prematurely would continue to suffer delusion and hallucination and have insufficient judgment and insight. Psychiatric wards in general hospitals should cover acute-phase patients for at least this duration, if needed. Baldessarini noted that the response to neuroleptics occurs in two phases: rapid improvement over the first week or month, followed by slower improvement over the course of the next 3–25 weeks [18]. Osser and Patterson considered 8 weeks as an adequate trial of standard neuroleptics, assuming adequate bioavailability of the agent [19]. Marder suggests that most patients should be on antipsychotic medication at least 6 weeks [20]. However, these reports either did not distinguish responders from nonresponders or drew experience-based rather than evidence-based conclusions. The 5-week hospital stay concluded from the results of the present case-control study is shorter than stays recommended in previous reports because the 5 weeks is adequate only for good responders. For non- or poor-responders, several months might be needed before antipsychotic effects become apparent [21]. General hospitals cannot provide such prolonged treatment. So, early prediction of treatment response is valuable. On the other hand, 5 weeks for a hospital stay seems to be long when compared to periods concluded from medicoeconomic analyses of government agencies or insurance companies. However, on the clinical psychopharmacologic or scientific basis of our study, 5 weeks might be the limit (the shortest recommended hospital stay) even for good responders to antipsychotics. Despite the small number of subjects examined, a conservative claim can be made that Conceptual disorganization, Poor rapport, Passive/apathetic social withdrawal, Stereotyped thinking, and Negative Scale total scores seemed to be specific predictors of antipsychotic response at baseline. In particular, Conceptual disorganization and Negative Scale total scores may be the most sensitive and specific predictors of antipsychotic response at baseline. On the basis of the differences in the time course of clinical improvement, Excitement may have the most predictive value of antipsychotic response in 1 week. Lack of judgment and insight score in the responder group first changed significantly at 1 week (as did the Excitement score) and changed again at 5 weeks (as did the Delusion and Hallucinatory behavior scores). These results suggest that although only 1 week is needed for a sedating effect to appear, 5 weeks are needed for a true and sufficient antipsychotic effect, even in responders. Therefore, psychiatric wards in general hospitals should treat acute-phase patients for at least this duration, if needed. Acknowledgements  This work was supported in part by a grant from the Ministry of Health, Welfare, and Labor of Japanese Government to K.H. References  [1].
[1]
Currier GW, Allen MH.
Emergency psychiatry (physical and chemical restraint in the psychiatric emergency service).
Psychiatr Serv. 2000;51:717–719. MEDLINE |
CrossRef
[2].
[2]
Hatta K, Takahashi T, Nakamura H, et al.
Laboratory findings in acute schizophrenia (relevance to medical management on emergency admission).
Gen Hosp Psychiatry. 1999;21:220–227. Abstract | Full Text |
Full-Text PDF (486 KB)
|
CrossRef
[3].
[3]
Hatta K, Takahashi T, Nakamura H, et al.
Hypokalemia and agitation in acute psychotic patients.
Psychiatry Res. 1999;86:85–88. Abstract | Full Text |
Full-Text PDF (92 KB)
|
CrossRef
[4].
[4]
Hatta K, Takahashi T, Nakamura H, Yamashiro H, Yonezawa Y.
Prolonged QT interval in acute psychotic patients.
Psychiatry Res. 2000;94:279–285. Abstract | Full Text |
Full-Text PDF (105 KB)
|
CrossRef
[5].
[5]
Hatta K, Takahashi T, Nakamura H, et al.
A risk for obstruction of the airways in the parenteral use of levomepromazine with benzodiazepine.
Pharmacopsychiatry. 1998;31:126–130. MEDLINE |
CrossRef
[6].
[6]
Hatta K, Takahashi T, Nakamura H, et al.
Prolonged upper airway instability in parenteral use of benzodiazepine with levomepromazine.
J Clin Psychopharmacology. 2000;20:99–101. [7].
[7]
Hatta K, Takahashi T, Nakamura H, et al.
The association between intravenous haloperidol and prolonged QT interval.
J Clin Psychopharmacology. 2001;21:257–261. [8].
[8]
Kaplan HI, Sadock BJ.
Synopsis of Psychiatry. 8th Ed.. Baltimore: Lippincott, Williams, & Wilkins; 1998;. [9].
[9]
Lieberman J, Jody D, Geisler S, et al.
Time course and biologic correlates of treatment response in first-episode schizophrenia.
Arch Gen Psychiatry. 1993;50:369–376. [10].
[10]
Levinson DF, Singh H, Simpson GM.
Timing of acute clinical response to fluphenazine.
Br J Psychiatry. 1992;160:365–371. MEDLINE |
CrossRef
[11].
[11]
Lieberman J, Alvir J, Woerner M, et al.
Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital (design, methodology, and summary of findings).
Schizophr Bull. 1992;18:351–371. MEDLINE [12].
[12]
Lieberman JA, Alvir JM, Koreen A, et al.
Psychobiologic correlates of treatment response in schizophrenia.
Neuropsychopharmacology. 1996;14:13S–21S.
CrossRef
[13].
[13]
Kinon BJ, Kane JM, Chakos M, Munne R.
Possible predictors of neuroleptic-resistant schizophrenic relapse (influence of negative symptoms and acute extrapyramidal side effects).
Psychopharmacol Bull. 1993;29:365–369. MEDLINE [14].
[14]
World Health Organization
.
The ICD-10 Classification of Mental and Behavioural Disorders (Clinical Descriptions and Diagnostic Guidelines). Geneva: WHO; 1992;. [15].
[15]
Key SR, Opler LA, Fiszbein A.
Positive and Negative Syndrome Scale (PANSS) Rating Manual. Toronto: Multi-Health System Inc; 1991;. [16].
[16]
Van Os J, Fahy TA, Jones P, et al.
Psychopathological syndromes in the functional psychoses (associations with course and outcome).
Psychol Med. 1996;26:161–176. MEDLINE |
CrossRef
[17].
[17]
Smith TE, Hull JW, Goodman M, et al.
The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder.
J Nerv Ment Dis. 1999;187:102–108. MEDLINE |
CrossRef
[18].
[18]
Baldessarini RJ.
Chemotherapy in Psychiatry. Cambridge: Harvard University Press; 1985;. [19].
[19]
Osser DN, Patterson RD.
Pharmacotherapy of schizophrenia 1 (acute treatment).
In:
Soreff SM editors. Handbook for the treatment of the seriously mentally ill. Seattle: Hogrefe & Huber; 1996;p. 91–119. [20].
[20]
Marder SR.
Management of treatment-resistant patients with schizophrenia.
J Clin Psychiatry. 1996;57(Suppl 11):26–30. [21].
[21]
Meltzer HY.
Treatment of the neuroleptic-nonresponsive schizophrenic patient.
Schizophrenia Bull. 1992;18:515–542. a Department of Psychiatry, Juntendo University School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan b Department of Public Health, Kanazawa University School of Medicine, Kanazawa, Japan c Institute of Community Medicine, University of Tsukuba, Tsukuba, Japan Corresponding author. Tel.: +81-3-5802-1071; fax: +81-3-5802-1071.
PII: S0163-8343(02)00252-9 doi:10.1016/S0163-8343(02)00252-9 © 2003 Elsevier Science Inc. All rights reserved. | |
|